{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:29:07Z","timestamp":1789770547605,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["psy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.psychres.2015.12.033","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T12:46:15Z","timestamp":1451306775000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone"],"prefix":"10.1016","volume":"237","author":[{"given":"Ying","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suoyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psychres.2015.12.033_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0306-3356(21)00235-1","article-title":"Endocrinology of sexual function","volume":"7","author":"Bancroft","year":"1980","journal-title":"Clin. Obstet. Gynaecol."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2015.12.033_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.schres.2004.06.013","article-title":"Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics","volume":"73","author":"Bergemann","year":"2005","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2015.12.033_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1345\/aph.1C297","article-title":"Aripiprazole: a new atypical antipsychotic drug","volume":"37","author":"Bowles","year":"2003","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.psychres.2015.12.033_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.psychres.2015.12.033_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2015.12.033_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2015.12.033_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(02)00123-3","article-title":"Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder","volume":"111","author":"Canuso","year":"2002","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.psychres.2015.12.033_bib8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2015.12.033_bib9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2015.12.033_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"7","key":"10.1016\/j.psychres.2015.12.033_bib11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4088\/JCP.08l04671","article-title":"Aripiprazole treatment of risperidone-induced hyperprolactinemia","volume":"70","author":"Chen","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2015.12.033_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.psychres.2015.12.033_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/070674370404900213","article-title":"Aripirazole-olanzapine combination for treatment of schizophrenia","volume":"49","author":"Duggal","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2015.12.033_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","article-title":"Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics","volume":"5","author":"Faries","year":"2005","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2015.12.033_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1017\/S1461145712000399","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"17","author":"Fleischhacker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2015.12.033_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.schres.2007.09.002","article-title":"Antipsychotic polypharmacy does not increase the risk for side effects","volume":"98","author":"Ganesan","year":"2008","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2015.12.033_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.jcp.0000196417.44847.0b","article-title":"Aripiprazole as a dopamine partial agonist: positive and negative effects","volume":"26","author":"Glick","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.12.033_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.physiol.64.081501.131049","article-title":"Prolactin: the new biology of an old hormone","volume":"64","author":"Goffin","year":"2002","journal-title":"Annu. Rev. Physiol."},{"issue":"7","key":"10.1016\/j.psychres.2015.12.033_bib19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","article-title":"Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008,\u00a0Nice","volume":"19","author":"Goodwin","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"20","key":"10.1016\/j.psychres.2015.12.033_bib20","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.psychres.2015.12.033_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects","volume":"9","author":"Halbreich","year":"2003","journal-title":"J. Psychiatr. Pract."},{"issue":"2","key":"10.1016\/j.psychres.2015.12.033_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management","volume":"74","author":"Holt","year":"2010","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"10.1016\/j.psychres.2015.12.033_bib23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4088\/JCP.v68n0302","article-title":"Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder","volume":"68","author":"Howes","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2015.12.033_bib24","first-page":"147","article-title":"The progress of research on hyperprolactinemia","volume":"23","author":"Hui","year":"2004","journal-title":"J. Int. Reprod. Health\/Fam. Plan."},{"issue":"6","key":"10.1016\/j.psychres.2015.12.033_bib25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/JCP.0b013e31818ba5d8","article-title":"Antipsychotic-induced hyperprolactinemia: a cross-sectional survey","volume":"28","author":"Johnsen","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2015.12.033_bib26","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2015.12.033_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","article-title":"Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic","volume":"12","author":"Keck","year":"2003","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.psychres.2015.12.033_bib28","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"26","key":"10.1016\/j.psychres.2015.12.033_bib29","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJM198012253032605","article-title":"Decreased bone density in hyperprolactinemic women","volume":"303","author":"Klibanski","year":"1980","journal-title":"N Engl. J. Med."},{"issue":"2","key":"10.1016\/j.psychres.2015.12.033_bib30","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S0306-4530(02)00130-0","article-title":"What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?","volume":"28","author":"Knegtering","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.psychres.2015.12.033_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psyneuen.2008.08.015","article-title":"Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia","volume":"34","author":"Konarzewska","year":"2009","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.psychres.2015.12.033_bib32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","article-title":"Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study","volume":"30","author":"Lee","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2015.12.033_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.9758\/cpn.2013.11.2.60","article-title":"Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone","volume":"11","author":"Lee","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"6","key":"10.1016\/j.psychres.2015.12.033_bib34","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","article-title":"Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.psychres.2015.12.033_bib35","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.psychres.2015.12.033_bib36","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"Lu","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2015.12.033_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics \u2013 a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2015.12.033_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2015.12.033_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients","volume":"66","author":"Melkersson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2015.12.033_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1017\/S1461145706007115","article-title":"Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole","volume":"10","author":"Paulzen","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2015.12.033_bib41","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2015.12.033_bib42","first-page":"549","article-title":"Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia","volume":"11","author":"Ranjbar","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.psychres.2015.12.033_bib43","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","article-title":"A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes","volume":"41","author":"Robinson","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.psychres.2015.12.033_bib44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.pnpbp.2010.06.003","article-title":"Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia","volume":"34","author":"Rocha","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2015.12.033_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000063574","article-title":"Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels","volume":"46","author":"Schlosser","year":"2002","journal-title":"Neuropsychobiology"},{"issue":"8","key":"10.1016\/j.psychres.2015.12.033_bib46","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","article-title":"Gender differences in the prescribing of antipsychotic drugs","volume":"161","author":"Seeman","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2015.12.033_bib47","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2015.12.033_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","article-title":"The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis","volume":"22","author":"Smith","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2015.12.033_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.008","article-title":"Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors","volume":"597","author":"Tadori","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2015.12.033_bib50","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.psychres.2015.12.033_bib51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ppc.12050","article-title":"Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China","volume":"50","author":"Wang","year":"2014","journal-title":"Perspect. Psychiatr. Care"},{"issue":"5","key":"10.1016\/j.psychres.2015.12.033_bib52","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2015.12.033_bib53","doi-asserted-by":"crossref","first-page":"e0139717","DOI":"10.1371\/journal.pone.0139717","article-title":"Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial","volume":"10","author":"Zhao","year":"2015","journal-title":"PloS One"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115308799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115308799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T17:39:11Z","timestamp":1653932351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178115308799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":53,"alternative-id":["S0165178115308799"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2015.12.033","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2015.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}